This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Myers JL, El-Zammar O . Pathology of drug-induced lung disease. In: Katzenstein AL (ed). Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease, 4th edn. Elsevier Publishing Ltd: Philadelphia, PA, 2006, pp 85–89.
Kalaycio M, Pohlman B, Kuczkowski E, Rybicki L, Andresen S, Sobecks R et al. High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clin Transplant 2006; 20: 783–787.
Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP et al. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416: 426–432.
Li CK, Yuen PM, Wong R, Pang CP, Lai WK, Chik KW et al. Busulphan level and early mortality in thalassaemia patients after BMT. Bone Marrow Transplant 1999; 23: 307–310.
Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.
Czerwinksi M, Gibbs JP, Slattery JT . Busulfan conjugation by glutathione S-transferases alpha, mu and pi. Drug Metab Dispos 1996; 24: 1015–1019.
Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008; 48: 1052–1062.
Nguyen L, Leger F, Lennon S, Puozzo C . Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191–198.
Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113–123.
Stein J, Davidovitz M, Yaniv I, Ben-Ari J, Gamzu Z, Hoffer E et al. Accidental busulfan overdose: enhanced drug clearance with hemodialysis in a child with Wiskott-Aldrich syndrome. Bone Marrow Transplant 2001; 27: 551–553.
Acknowledgements
This work was supported in part by funds for Clinical Cancer Research from the Health and Labour Sciences Research Grants.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishikawa, T., Okamoto, Y., Tanabe, T. et al. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation. Bone Marrow Transplant 45, 602–604 (2010). https://doi.org/10.1038/bmt.2009.195
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.195
This article is cited by
-
Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients
International Journal of Hematology (2015)
-
Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children
International Journal of Hematology (2010)